Aisling Capital

GondolaBio is a biopharmaceutical company dedicated to researching, developing, and manufacturing pharmaceutical products. Its primary focus is on creating therapeutics for patients with genetic diseases, addressing high unmet needs across various therapeutic areas and stages of development. The company leverages biological research to drive its mission, aiming to enable the healthcare industry to effectively treat and manage rare genetic conditions.

CalciMedica, Inc. is a clinical-stage biopharmaceutical company based in La Jolla, California, specializing in the discovery and development of small molecule drugs aimed at treating autoimmune and inflammatory diseases. Founded in December 2006 by a team of scientists with backgrounds in the field, the company focuses on the specific inhibition of calcium release-activated calcium channels. This innovative approach seeks to modulate the immune response and protect against tissue cell injury, addressing significant unmet medical needs in life-threatening inflammatory conditions for which existing therapies are lacking. CalciMedica's proprietary technology has the potential to offer therapeutic benefits in these challenging areas of healthcare.

Garuda Therapeutics is a biotech company focused on developing off-the-shelf hematopoietic stem cell therapies aimed at treating life-threatening diseases, particularly those affecting blood, bone marrow, immunity, and metabolism. The company is dedicated to eliminating the reliance on donor or patient cells for blood stem cell transplants by leveraging its innovative platform technology to generate self-renewing blood stem cells. This approach is designed to ensure rapid and broad access to consistent, durable, HLA-compatible, and transgene-free blood stem cell therapies for patients. Garuda Therapeutics employs advanced methodologies, including the use of zebrafish, mice, and human-induced pluripotent stem cells, to clone and analyze novel genes and mechanisms critical for blood formation, ultimately developing mechanism-based therapies that address unmet medical needs.

Forge Biologics, Inc. is a contract development and manufacturing organization based in Columbus, Ohio, focused on developing and manufacturing gene therapies and genetic medicines. The company specializes in viral vector gene therapies aimed at treating genetic diseases, including a novel approach combining adeno-associated virus (AAV) with umbilical cord transplants for infantile Krabbe disease, a severe neurodegenerative condition. Founded in 2019, Forge Biologics partners with scientists, healthcare professionals, and biotech and pharmaceutical companies to facilitate the transition of gene therapy programs from preclinical development to clinical and commercial-scale production. By providing end-to-end capabilities, the company aims to accelerate the availability of transformative medicines for patients suffering from rare genetic disorders.

Dren Bio is a biotechnology company that specializes in protein engineering technologies designed to target and deplete pathogenic cells, protein aggregates, and other disease-causing agents. With a focus on hematologic neoplasms, solid cancers, autoimmune disorders, and diseases related to protein aggregation, the company aims to provide innovative solutions for healthcare professionals in their efforts to combat various serious diseases. Operating under a holding company model, Dren Bio develops multiple projects as standalone assets, seeking to create value through its diverse portfolio of biotechnology initiatives.

Garuda Therapeutics is a biotech company focused on developing off-the-shelf hematopoietic stem cell therapies aimed at treating life-threatening diseases, particularly those affecting blood, bone marrow, immunity, and metabolism. The company is dedicated to eliminating the reliance on donor or patient cells for blood stem cell transplants by leveraging its innovative platform technology to generate self-renewing blood stem cells. This approach is designed to ensure rapid and broad access to consistent, durable, HLA-compatible, and transgene-free blood stem cell therapies for patients. Garuda Therapeutics employs advanced methodologies, including the use of zebrafish, mice, and human-induced pluripotent stem cells, to clone and analyze novel genes and mechanisms critical for blood formation, ultimately developing mechanism-based therapies that address unmet medical needs.

Biomea Fusion is a preclinical-stage biopharmaceutical company dedicated to advancing precision medicine for cancer treatment. The company's focus is on the discovery and development of irreversible small molecule drugs that target specific genetic alterations associated with tumor growth. Its lead product candidate, BMF-219, is designed as a potent and selective irreversible inhibitor of menin, a key transcriptional regulator involved in oncogenic signaling across various cancers. Biomea Fusion aims to expedite the development of these innovative therapies to provide highly effective treatment options for patients with genetically defined cancers.

Reneo Pharmaceuticals is a clinical-stage pharmaceutical company based in San Diego, California, that focuses on developing therapies for patients with rare genetic mitochondrial diseases. These conditions are linked to defects in energy metabolism, leading to issues such as muscle weakness and wasting. The company is developing REN001, an oral drug designed to modulate genes involved in mitochondrial function, aiming to enhance adenosine triphosphate (ATP) production, which is essential for cellular energy. By improving mitochondrial activity, Reneo seeks to enhance the daily functioning and quality of life for patients suffering from these disorders. Founded in 2014, Reneo Pharmaceuticals is committed to addressing the needs of individuals with orphan metabolic diseases.

Monte Rosa Therapeutics is a biotechnology company focused on developing innovative cancer therapeutics that utilize molecular glue degraders (MGDs) to modulate protein degradation pathways. By leveraging the body's natural mechanisms for protein destruction, these small molecule drugs selectively target and degrade disease-causing proteins. The company employs its QuEEN platform, which combines artificial intelligence and proprietary experimental tools, to identify relevant proteins for degradation. With a diverse library of over 50,000 MGD molecules, Monte Rosa's lead candidate, MRT-2359, specifically targets the translation termination factor protein GSPT1, showing promise for treating MYC-driven tumors. The company aims to advance its pipeline of pioneering therapies for cancer and other diseases.

Elevation Oncology, Inc. is a biotechnology company dedicated to developing precision medicines for patients with genomically defined cancers. The company focuses on creating targeted therapeutics that inhibit specific genetic alterations known to drive cancer progression. Its lead drug candidate, seribantumab, targets neuregulin-1 (NRG1) fusions, which are rare genomic alterations that can be treated through targeted HER3 inhibition. Currently, seribantumab is undergoing clinical testing in the Phase 2 CRESTONE study, which evaluates its efficacy in patients with solid tumors of any origin that harbor NRG1 fusions. Founded in 2019 and based in New York, Elevation Oncology aims to make genomic tests actionable by selectively developing drugs that address these specific alterations in cancer patients.

Spruce Biosciences, Inc. is a biopharmaceutical company dedicated to developing and commercializing innovative therapies for rare endocrine disorders, particularly those affecting the hypothalamic-pituitary-adrenal axis. Founded in 2014 and headquartered in Daly City, California, the company is advancing its lead product candidate, tildacerfont, which is currently undergoing Phase IIb clinical trials for adult patients and Phase II clinical trials for children with classic congenital adrenal hyperplasia (CAH). Tildacerfont is positioned as a potential first non-steroidal therapy that aims to improve disease control and reduce the reliance on steroids for patients with CAH. Additionally, Spruce is exploring the use of tildacerfont for women with polycystic ovary syndrome. The company has also entered into a licensing agreement with Eli Lilly and Company to research and develop compounds for various pharmaceutical applications.

Nuvation Bio Inc. is a biopharmaceutical company dedicated to addressing unmet needs in oncology through the development of novel therapies for challenging cancers. Founded in 2018 and headquartered in New York, with an additional office in San Francisco, Nuvation Bio focuses on treating patients whose conditions have not responded to conventional treatments. The company's leading clinical-stage candidate, NUV-868, is a BD2-selective oral small molecule BET inhibitor that targets the BRD4 protein, which plays a crucial role in regulating tumor growth and differentiation. In addition to NUV-868, Nuvation Bio is advancing a proprietary small molecule Drug-Drug Conjugate platform aimed at enhancing therapeutic efficacy. The company’s comprehensive portfolio includes multiple drug development candidates designed to meet the specific needs of cancer patients.

Ajax Health, established in 2017, is a venture capital firm headquartered in Menlo Park, California, with an additional office in New York City. The company specializes in investing in innovative medical device companies, digital health, healthcare services, and biotechnology across all stages of a company's lifecycle. Ajax Health seeks to accelerate medical innovation by providing capital and strategic capabilities to address major healthcare issues.

Poseida Therapeutics is a clinical-stage biopharmaceutical company based in San Diego, California, dedicated to developing innovative therapeutics for patients with significant unmet medical needs. The company utilizes non-viral gene engineering technologies to create a pipeline of targeted therapies, including both autologous and allogeneic chimeric antigen receptor T cell (CAR-T) product candidates aimed at treating hematological malignancies and solid tumors. Additionally, Poseida is advancing gene therapies for rare and life-threatening conditions, such as Ornithine transcarbamylase deficiency, methylmalonic acidemia, and various genetic liver diseases. Founded in 2014, Poseida is committed to addressing critical health challenges through its focused research and development efforts.

Ajax Health, established in 2017, is a venture capital firm headquartered in Menlo Park, California, with an additional office in New York City. The company specializes in investing in innovative medical device companies, digital health, healthcare services, and biotechnology across all stages of a company's lifecycle. Ajax Health seeks to accelerate medical innovation by providing capital and strategic capabilities to address major healthcare issues.

BridgeBio is a biotechnology company that focuses on genetic disease therapies and develops those assets with the right approach in supporting R&D. BridgeBio creates a bridge from advancements in genetic science to patients with unmet needs via the entrepreneurial engine required to make life-changing medicines as rapidly as possible. BridgeBio's mission is to discover, create, test, and deliver transformative medicines to treat patients with genetic diseases.

Atreca, Inc. is a biopharmaceutical company based in South San Francisco, California, focused on discovering and developing antibody-based immunotherapeutics for various solid tumor types. Its lead product candidate, ATRC-101, is a monoclonal antibody currently in clinical development, characterized by a novel mechanism of action. ATRC-101 has demonstrated reactivity in vitro with a significant majority of human cancer samples, including ovarian, non-small cell lung, colorectal, and breast cancers. Atreca employs a unique technology to identify antibodies produced during immune responses without prior knowledge of antigens. The company collaborates strategically with Merck Sharp & Dohme Corp. to pinpoint antigenic targets of selected antibodies that may have applications in oncology. Founded in 2010, Atreca is dedicated to advancing innovative treatments for cancer.

Ajax Health, established in 2017, is a venture capital firm headquartered in Menlo Park, California, with an additional office in New York City. The company specializes in investing in innovative medical device companies, digital health, healthcare services, and biotechnology across all stages of a company's lifecycle. Ajax Health seeks to accelerate medical innovation by providing capital and strategic capabilities to address major healthcare issues.

Eidos Therapeutics, Inc. is a clinical stage biopharmaceutical company based in San Francisco, California, that specializes in developing treatments for diseases related to transthyretin (TTR) amyloidosis. The company is advancing AG10, an orally administered small molecule currently in phase 3 clinical trials, which aims to stabilize tetrameric TTR and interrupt the molecular processes leading to amyloidosis. Founded in 2013, Eidos Therapeutics operates as a subsidiary of BridgeBio Pharma, which focuses on creating genetically targeted therapies designed to address the underlying causes of various diseases. Through its innovative approach, Eidos Therapeutics seeks to provide potentially disease-modifying therapies to meet the significant medical needs associated with TTR-related conditions.

Zosano Pharma Corporation is a clinical-stage biopharmaceutical company headquartered in Fremont, California, established in 2006. The company specializes in developing innovative drug delivery technologies aimed at addressing unmet medical needs. Its primary focus is on providing therapeutics for migraine sufferers through its proprietary intracutaneous microneedle system, which facilitates rapid systemic administration and absorption of medications. Zosano's lead product candidate, Qtrypta (M207), is a formulation of zolmitriptan designed to offer an improved pharmacokinetic profile compared to traditional dosage forms. By leveraging its advanced delivery system, Zosano Pharma aims to enhance patient outcomes and expand the potential for commercialization of its therapeutic products.

Avrobio is a clinical-stage gene therapy company based in Cambridge, Massachusetts, focused on developing ex vivo lentiviral gene therapies aimed at treating rare diseases with a single-dose approach. The company utilizes hematopoietic stem cells collected from patients, which are modified using a lentiviral vector to insert functional copies of defective genes associated with specific diseases. Avrobio's lead product candidate, AVR-RD-01, is currently in Phase II clinical trials for Fabry disease. Additionally, the company's pipeline includes AVR-RD-02, which has completed preclinical trials for type 1 Gaucher disease; AVR-RD-03, in preclinical development for Pompe disease; and AVR-RD-04, which has also completed preclinical studies for cystinosis. Avrobio has established a research collaboration with Magenta Therapeutics to explore targeted antibody-drug conjugates as a conditioning regimen for its lentiviral gene therapies. Founded in 2015, Avrobio aims to leverage advancements in cell and gene therapies to provide potential cures for serious and debilitating conditions.

ObsEva SA is a clinical-stage biopharmaceutical company based in Geneva, Switzerland, dedicated to developing innovative therapeutics for women's reproductive health and pregnancy. Founded in 2012 by Ernest Loumaye and André Chollet, the company focuses on addressing serious conditions such as endometriosis, heavy menstrual bleeding, and preterm labor. Its key products include Linzagolix, an oral gonadotropin-releasing hormone receptor antagonist aimed at treating pain from endometriosis and uterine fibroids, and OBE022, a selective prostaglandin F2α receptor antagonist designed for once-daily treatment of preterm labor. Additionally, ObsEva is advancing Nolasiban, an oral oxytocin receptor antagonist intended to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization. The company operates primarily in Switzerland and is committed to improving outcomes for women facing reproductive health challenges.

GTx, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative treatments for stress urinary incontinence and prostate cancer. The company specializes in selective androgen receptor modulators (SARMs) and selective androgen receptor degraders, targeting conditions such as breast cancer and Duchenne muscular dystrophy. One of its notable product candidates is enobosarm GTx-024, which is undergoing Phase II clinical trials for patients with specific types of breast cancer and postmenopausal women suffering from stress urinary incontinence. Founded in 1997 and based in Memphis, Tennessee, GTx aims to advance medical solutions by leveraging new scientific approaches. In 2019, GTx was acquired by Oncternal Therapeutics in a reverse merger.

BridgeBio is a biotechnology company that focuses on genetic disease therapies and develops those assets with the right approach in supporting R&D. BridgeBio creates a bridge from advancements in genetic science to patients with unmet needs via the entrepreneurial engine required to make life-changing medicines as rapidly as possible. BridgeBio's mission is to discover, create, test, and deliver transformative medicines to treat patients with genetic diseases.

VYNE Therapeutics Inc. is a biopharmaceutical company specializing in the development and commercialization of innovative therapies for dermatological conditions. It offers AMZEEQ, a topical minocycline treatment for non-nodular moderate-to-severe acne vulgaris in patients aged 9 and older. The company is advancing its pipeline with FMX103, currently in Phase III clinical trials for moderate-to-severe papulopustular rosacea in adults, and FCD105, a topical combination foam under investigation in Phase II trials for moderate-to-severe acne vulgaris. Additionally, VYNE is developing Serlopitant, an oral NK1 receptor antagonist aimed at addressing pruritus associated with prurigo nodularis, as well as exploring therapies for other immuno-inflammatory conditions. Formerly known as Menlo Therapeutics Inc., the company rebranded in September 2020 and is headquartered in Bridgewater, New Jersey.

Promentis Pharmaceuticals, Inc. is a biopharmaceutical company based in Milwaukee, Wisconsin, established in 2006. The company specializes in developing therapies for neuropsychiatric disorders, with a focus on addressing glutamatergic imbalance and oxidative stress. Promentis is known for its lead compound, SXC-2023, which targets System xc- to treat multiple conditions, including impulse control disorders and obsessive-compulsive disorder. In addition to SXC-2023, Promentis is also working on other compounds aimed at restoring glutamatergic neurotransmission, which is crucial for improving cortical function and managing various psychiatric disorders, including schizophrenia.

Ajax Health, established in 2017, is a venture capital firm headquartered in Menlo Park, California, with an additional office in New York City. The company specializes in investing in innovative medical device companies, digital health, healthcare services, and biotechnology across all stages of a company's lifecycle. Ajax Health seeks to accelerate medical innovation by providing capital and strategic capabilities to address major healthcare issues.

Prolacta Bioscience Inc. is a life science company dedicated to improving the health of premature and critically ill infants in neonatal intensive care units (NICUs) through the development of standardized human milk-based nutritional products. Founded in 1999 and headquartered in Duarte, California, Prolacta specializes in creating unique formulations exclusively made from human milk, including human milk fortifiers, caloric fortifiers, and ready-to-feed formulas. Notably, it is the only company that offers a human milk fortifier composed entirely of 100% human milk, known as Prolact+ H2MF. The company operates a pharmaceutical-grade processing facility that employs patented methods to ensure the safety and quality of its products. Prolacta Bioscience is committed to advancing the science of human milk and making a significant impact on the lives of vulnerable infants through innovative research and specialized nutritional solutions.

Verona Pharma is a clinical-stage biopharmaceutical company based in London, established in 2005. The company specializes in developing and commercializing therapies for respiratory diseases that have significant unmet medical needs, including chronic obstructive pulmonary disease (COPD), cystic fibrosis, and asthma. Its lead product candidate, ensifentrine, is an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, functioning as both a bronchodilator and an anti-inflammatory agent. Ensifentrine is being developed in various formulations, including nebulized, dry powder inhaler, and pressurized metered-dose inhaler, with the nebulized form currently in Phase 2b clinical development for the maintenance treatment of COPD. Verona Pharma's commitment is to enhance the health and quality of life for individuals suffering from chronic respiratory conditions through innovative therapeutic solutions.

F2G Ltd is a biotechnology company based in Manchester, United Kingdom, that specializes in developing innovative therapies for serious fungal diseases. Established in 1998, F2G focuses on its F3 series of antifungal compounds, particularly targeting challenging fungi such as Aspergillus and other filamentous molds that pose significant health risks. The company leverages its proprietary genomics technology, MycoBank, to identify critical gene targets in fungi, facilitating the creation of effective antifungal agents. Since its initial funding in 2002, F2G has expanded its research and development capabilities, enabling it to advance its patented compounds and contribute to addressing life-threatening fungal infections that affect individuals with compromised immune systems.

Earlens is a medical technology company focused on improving the hearing experience for individuals with hearing loss. It has created the Earlens Contact Hearing Solution, a unique device that directly stimulates the eardrum using a small lens, replicating the natural hearing process. Unlike conventional hearing aids that amplify sound, the Earlens solution delivers sound directly to the eardrum, providing superior sound quality and a broader bandwidth. This innovative, non-surgical approach allows for automatic adjustments in challenging listening environments while minimizing feedback. The technology received FDA clearance in 2019 for its second generation, marking a significant advancement in hearing solutions aimed at enhancing the quality of life for those with hearing impairment.

Aclaris Therapeutics is a clinical-stage biopharmaceutical company based in the United States, specializing in the development of innovative therapies for dermatological and immuno-inflammatory conditions. Founded by the creators of Vicept Therapeutics, the company is dedicated to addressing significant unmet needs in these fields, focusing on areas where no FDA-approved treatments exist or where treatment options are limited. Aclaris operates primarily in two segments: therapeutics and contract research. The therapeutics segment is engaged in the identification and development of novel drug candidates, while the contract research segment generates revenue through laboratory services. Among its developmental candidates is Zunsemetinib, an oral MK2 inhibitor aimed at treating immuno-inflammatory diseases.

Miramar Labs is a company based in Sunnyvale, California, that specializes in developing medical devices for aesthetic purposes, particularly focusing on the treatment of primary axillary hyperhidrosis in adults. Founded in 2006, the company offers the miraDry System, which provides a non-invasive solution for excessive sweating and odor. This system employs microwave energy to selectively target and permanently eliminate sweat and odor glands in the underarm area. By addressing these concerns, Miramar Labs aims to enhance the confidence and quality of life for individuals suffering from this condition. However, the miraDry System is not designed to treat hyperhidrosis in other areas of the body, such as the hands and feet.

PowerVision, Inc. is a company that specializes in the development of innovative intraocular lenses aimed at restoring vision for individuals suffering from presbyopia and cataracts. Founded in 2002 and based in Belmont, California, PowerVision has created the FluidVision accommodating intraocular lens, which utilizes a unique fluid-controlled mechanism to mimic the natural function of a healthy eye. This technology allows users to dynamically adjust their focus for clear vision at all distances, potentially liberating millions from the need for glasses or other vision correction methods. The FluidVision lens is designed to meet the clinical and lifestyle needs of patients, offering a significant advancement in vision correction surgery. PowerVision's approach addresses the visual impairments faced by over 20 million people in the United States with cataracts and more than 90 million individuals affected by presbyopia, particularly those in their 40s and 50s.

Zavante Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, dedicated to developing innovative treatments for patients in hospital settings. The company's primary focus is on ZOLYD, an investigational injectable antibiotic designed to address serious and life-threatening infections, including those caused by multi-drug resistant gram-negative and gram-positive bacteria. Incorporated in 2013, Zavante aims to enhance patient outcomes through its novel therapeutic approaches. As of July 2018, it operates as a subsidiary of Nabriva Therapeutics plc.

Spirox, Inc., based in Menlo Park, California, is a medical device company focused on improving the quality of life for patients with nasal obstruction, particularly those suffering from nasal valve collapse (NVC). Formerly known as Nasoform, Spirox has developed the LATERA absorbable nasal implant, which offers a minimally invasive treatment option for this common yet often undertreated condition. The implant addresses weakened lateral wall cartilage, a significant contributor to nasal airway obstruction. Founded in 2011, Spirox aims to complete product development, secure marketing authorization in the United States, and initiate commercialization efforts to make their innovative solution available to patients. As of July 2017, Spirox operates as a subsidiary of Entellus Medical, Inc.

Syros Pharmaceuticals, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, that specializes in developing innovative treatments for cancer and monogenic diseases through gene control medicines. The company is advancing its lead product candidates, including SY-1425, a selective retinoic acid receptor alpha agonist currently in Phase II clinical trials for specific patient populations with acute myeloid leukemia and myelodysplastic syndrome, and SY-5609, a cyclin-dependent kinase 7 inhibitor under investigation in a Phase I clinical trial for advanced solid tumors. Syros is also engaged in collaborative research, including a partnership with Incyte Corporation aimed at identifying therapeutic targets for myeloproliferative neoplasms and a licensing agreement with TMRC Co. Ltd. for the development of tamibarotene. With a focus on mapping gene regulatory circuits, Syros leverages its proprietary platform and expertise to address significant unmet medical needs in oncology. Founded in 2011, the company aims to establish new standards of care for patients with hematologic malignancies.

ViewRay, Inc. is a company that designs, manufactures, and markets advanced radiation therapy systems for cancer treatment. Its primary product, MRIdian, is an MRI-guided radiation therapy system that allows for simultaneous imaging and treatment of cancer patients. This innovative system integrates MRI technology, radiation delivery, and proprietary software to accurately locate and track soft-tissue tumors, enabling precise targeting while minimizing radiation exposure to surrounding healthy tissues. By providing real-time imaging during treatment, MRIdian addresses significant limitations of traditional radiation therapy methods, enhancing the safety and effectiveness of cancer treatment. ViewRay serves a diverse clientele, including university hospitals, community hospitals, private practices, government institutions, and independent cancer centers, primarily in the United States and internationally. The company was founded in 2004 and is headquartered in Oakwood, Ohio.

Spirox, Inc., based in Menlo Park, California, is a medical device company focused on improving the quality of life for patients with nasal obstruction, particularly those suffering from nasal valve collapse (NVC). Formerly known as Nasoform, Spirox has developed the LATERA absorbable nasal implant, which offers a minimally invasive treatment option for this common yet often undertreated condition. The implant addresses weakened lateral wall cartilage, a significant contributor to nasal airway obstruction. Founded in 2011, Spirox aims to complete product development, secure marketing authorization in the United States, and initiate commercialization efforts to make their innovative solution available to patients. As of July 2017, Spirox operates as a subsidiary of Entellus Medical, Inc.

Cynapsus is a pharmaceutical company based in Toronto, Ontario, established in 2004, that focuses on developing innovative treatments for Parkinson's disease. The company specializes in creating a non-injectable sublingual thin film formulation, APL-130277, designed for the on-demand management of OFF episodes, which are debilitating periods when symptoms of Parkinson's worsen. Cynapsus has successfully completed a Phase two clinical trial for this product candidate, which utilizes apomorphine hydrochloride as its active ingredient. The company's work aims to enhance the quality of life for individuals living with Parkinson's disease by providing an alternative to traditional injectable therapies.

Aimmune Therapeutics is a biopharmaceutical company that focuses on developing and commercializing treatments for peanut and other food allergies. The company's primary product, PALFORZIA, is designed to desensitize patients to peanut allergens through a method known as Characterized Oral Desensitization Immunotherapy (CODIT). In addition to PALFORZIA, Aimmune is conducting research and development on other CODIT candidates, including AR201, which is in Phase II clinical trials for treating egg allergies in pediatric and young adult patients, as well as potential treatments for cow’s milk allergy. Aimmune has established strategic collaborations with Nestlé Health Science to advance food allergy therapies and has clinical partnerships with Regeneron and Sanofi to explore the use of PALFORZIA alongside additional treatments. Founded in 2011 and headquartered in Brisbane, California, Aimmune Therapeutics aims to provide innovative solutions for managing life-threatening food allergies.

Cidara Therapeutics is a biotechnology company based in San Diego, California, established in 2012. The company specializes in the discovery and development of innovative anti-infective therapies for serious diseases, particularly those that affect individuals with compromised immune systems. Its lead candidate, rezafungin acetate, is an antifungal agent designed to treat and prevent severe invasive fungal infections, such as candidemia and invasive candidiasis, which carry significant mortality risks. In addition to its antifungal efforts, Cidara is advancing its proprietary Cloudbreak platform, which focuses on developing antiviral Fc-conjugates aimed at preventing and treating various viral infections, including influenza, RSV, HIV, and coronavirus. Cidara's mission is to transform treatment and prevention strategies for life-threatening illnesses.

Agile Therapeutics is a women's healthcare company dedicated to addressing the unmet health needs of women through the development and commercialization of prescription contraceptive products. The company's lead product, Twirla, is a once-weekly transdermal patch that delivers a combination of levonorgestrel and ethinylestradiol, providing a non-daily contraceptive option. In addition to Twirla, Agile Therapeutics is advancing a pipeline of related products, including various regimens designed to offer customizable menstrual cycle management options, such as AG200-ER for extended cycles and AG200-SP for lighter periods. The firm's proprietary Skinfusion technology facilitates effective drug delivery through the skin. Headquartered in Princeton, New Jersey, Agile Therapeutics aims to enhance women's reproductive health by providing innovative contraceptive solutions.

LENSAR, Inc. is a commercial-stage medical device company based in Orlando, Florida, established in 2004. It specializes in the design, development, and marketing of advanced femtosecond laser systems aimed at improving cataract surgery outcomes. The company's flagship product, the LENSAR Laser with Streamline IV, enhances the precision and efficiency of refractive cataract surgery by incorporating advanced features such as superior imaging capabilities and customizable treatment planning. This system assists surgeons in managing astigmatism and optimizing refractive results through innovative technology like the proprietary Augmented Reality™ 3-D model and the IntelliAxis Refractive Capsulorhexis® feature. These advancements facilitate accurate toric intraocular lens alignment and streamline surgical workflows, ultimately improving patient outcomes. LENSAR continues to expand its platform's capabilities, enabling the treatment of additional corneal conditions and enhancing the overall surgical experience for both patients and surgeons.

Syros Pharmaceuticals, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, that specializes in developing innovative treatments for cancer and monogenic diseases through gene control medicines. The company is advancing its lead product candidates, including SY-1425, a selective retinoic acid receptor alpha agonist currently in Phase II clinical trials for specific patient populations with acute myeloid leukemia and myelodysplastic syndrome, and SY-5609, a cyclin-dependent kinase 7 inhibitor under investigation in a Phase I clinical trial for advanced solid tumors. Syros is also engaged in collaborative research, including a partnership with Incyte Corporation aimed at identifying therapeutic targets for myeloproliferative neoplasms and a licensing agreement with TMRC Co. Ltd. for the development of tamibarotene. With a focus on mapping gene regulatory circuits, Syros leverages its proprietary platform and expertise to address significant unmet medical needs in oncology. Founded in 2011, the company aims to establish new standards of care for patients with hematologic malignancies.

Miramar Labs is a company based in Sunnyvale, California, that specializes in developing medical devices for aesthetic purposes, particularly focusing on the treatment of primary axillary hyperhidrosis in adults. Founded in 2006, the company offers the miraDry System, which provides a non-invasive solution for excessive sweating and odor. This system employs microwave energy to selectively target and permanently eliminate sweat and odor glands in the underarm area. By addressing these concerns, Miramar Labs aims to enhance the confidence and quality of life for individuals suffering from this condition. However, the miraDry System is not designed to treat hyperhidrosis in other areas of the body, such as the hands and feet.

Dermira, Inc. is a biopharmaceutical company based in Menlo Park, California, that focuses on developing and commercializing therapies for dermatologic conditions in the United States. The company offers QBREXZA, a once-daily topical treatment for primary axillary hyperhidrosis in patients aged nine years and older. Additionally, Dermira is advancing several product candidates, including lebrikizumab, a monoclonal antibody currently in Phase IIb trials for moderate-to-severe atopic dermatitis, and glycopyrronium tosylate, which is in Phase III trials for hyperhidrosis. Dermira also has collaborations with other companies for the development and commercialization of its products, such as a partnership with UCB Pharma for Cimzia, aimed at treating chronic plaque psoriasis. Founded in 2010, Dermira aims to provide innovative solutions for dermatologists and their patients.

Paratek Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company based in Boston, Massachusetts, specializing in the development and commercialization of innovative therapies derived from novel tetracycline chemistry. The company’s lead product, NUZYRA, is a broad-spectrum antibiotic administered in both oral and intravenous forms, targeting adult patients with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections. Another significant product, SEYSARA, is designed for the treatment of moderate to severe acne vulgaris. Paratek has received Qualified Infectious Disease Product designation from the U.S. Food and Drug Administration for its lead antibiotic, reflecting its commitment to addressing urgent public health threats, including antibiotic resistance. The company maintains various collaboration agreements, including partnerships with Zai Lab and Allergan, as well as research agreements with academic institutions and military organizations, to further its mission in combating infectious diseases and exploring additional therapeutic areas such as multiple sclerosis and systemic inflammatory diseases.

Cidara Therapeutics is a biotechnology company based in San Diego, California, established in 2012. The company specializes in the discovery and development of innovative anti-infective therapies for serious diseases, particularly those that affect individuals with compromised immune systems. Its lead candidate, rezafungin acetate, is an antifungal agent designed to treat and prevent severe invasive fungal infections, such as candidemia and invasive candidiasis, which carry significant mortality risks. In addition to its antifungal efforts, Cidara is advancing its proprietary Cloudbreak platform, which focuses on developing antiviral Fc-conjugates aimed at preventing and treating various viral infections, including influenza, RSV, HIV, and coronavirus. Cidara's mission is to transform treatment and prevention strategies for life-threatening illnesses.

PowerVision, Inc. is a company that specializes in the development of innovative intraocular lenses aimed at restoring vision for individuals suffering from presbyopia and cataracts. Founded in 2002 and based in Belmont, California, PowerVision has created the FluidVision accommodating intraocular lens, which utilizes a unique fluid-controlled mechanism to mimic the natural function of a healthy eye. This technology allows users to dynamically adjust their focus for clear vision at all distances, potentially liberating millions from the need for glasses or other vision correction methods. The FluidVision lens is designed to meet the clinical and lifestyle needs of patients, offering a significant advancement in vision correction surgery. PowerVision's approach addresses the visual impairments faced by over 20 million people in the United States with cataracts and more than 90 million individuals affected by presbyopia, particularly those in their 40s and 50s.

Loxo Oncology, Inc. is a biopharmaceutical company based in Stamford, Connecticut, focused on developing and commercializing targeted therapies for genetically defined cancers in the United States. Founded in 2013, the company aims to bring innovative cancer treatments to the clinic by identifying actionable "driver mutations" in tumors. Its lead product candidate, larotrectinib, is an oral selective inhibitor of tropomyosin receptor kinase (TRK) and is undergoing various clinical trials for multiple cancer types, including lung, melanoma, and breast cancer. Loxo Oncology is also advancing several preclinical programs, including candidates targeting RET fusion proteins and FGFR isoforms. The company has established collaborations with several organizations to enhance its drug discovery efforts and optimize its clinical development strategies. As a subsidiary of Eli Lilly and Company, Loxo Oncology is dedicated to creating effective therapies that address specific genetic vulnerabilities in cancer patients.

Earlens is a medical technology company focused on improving the hearing experience for individuals with hearing loss. It has created the Earlens Contact Hearing Solution, a unique device that directly stimulates the eardrum using a small lens, replicating the natural hearing process. Unlike conventional hearing aids that amplify sound, the Earlens solution delivers sound directly to the eardrum, providing superior sound quality and a broader bandwidth. This innovative, non-surgical approach allows for automatic adjustments in challenging listening environments while minimizing feedback. The technology received FDA clearance in 2019 for its second generation, marking a significant advancement in hearing solutions aimed at enhancing the quality of life for those with hearing impairment.

Versartis is a biotechnology company based in Redwood City, California, focused on developing therapeutic proteins for endocrine disorders. The company specializes in recombinant human growth hormones and employs a novel half-life extension technology known as XTEN to enhance treatment efficacy. Versartis is advancing its lead program, VRS-317, which has recently completed enrollment in a multi-center Phase 1 clinical study targeting adult patients with growth hormone deficiency. The company aims to improve patient compliance and treatment outcomes by reducing the frequency of daily injections associated with traditional therapies. Founded in December 2008 through a joint venture with Amunix Inc. and Index Ventures, Versartis is supported by a team of drug development experts and leverages external contract services to efficiently execute its product development strategies.

ViewRay, Inc. is a company that designs, manufactures, and markets advanced radiation therapy systems for cancer treatment. Its primary product, MRIdian, is an MRI-guided radiation therapy system that allows for simultaneous imaging and treatment of cancer patients. This innovative system integrates MRI technology, radiation delivery, and proprietary software to accurately locate and track soft-tissue tumors, enabling precise targeting while minimizing radiation exposure to surrounding healthy tissues. By providing real-time imaging during treatment, MRIdian addresses significant limitations of traditional radiation therapy methods, enhancing the safety and effectiveness of cancer treatment. ViewRay serves a diverse clientele, including university hospitals, community hospitals, private practices, government institutions, and independent cancer centers, primarily in the United States and internationally. The company was founded in 2004 and is headquartered in Oakwood, Ohio.

Seragon Pharmaceuticals, Inc., based in Irvine, California, is a research-focused biopharmaceutical company dedicated to enhancing human and animal health through innovative scientific advancements. The company specializes in the development of orally active selective estrogen receptor degraders (SERDs), particularly targeting metastatic breast cancer. Its lead drug candidate, ARN-810, is currently under evaluation for the treatment of estrogen receptor-positive breast cancer. By leveraging cutting-edge research in metabolism, gene therapy, and bioinformatics, Seragon Pharmaceuticals aims to facilitate access to significant medical breakthroughs, encompassing both clinical applications and consumer products.

Versartis is a biotechnology company based in Redwood City, California, focused on developing therapeutic proteins for endocrine disorders. The company specializes in recombinant human growth hormones and employs a novel half-life extension technology known as XTEN to enhance treatment efficacy. Versartis is advancing its lead program, VRS-317, which has recently completed enrollment in a multi-center Phase 1 clinical study targeting adult patients with growth hormone deficiency. The company aims to improve patient compliance and treatment outcomes by reducing the frequency of daily injections associated with traditional therapies. Founded in December 2008 through a joint venture with Amunix Inc. and Index Ventures, Versartis is supported by a team of drug development experts and leverages external contract services to efficiently execute its product development strategies.

Loxo Oncology, Inc. is a biopharmaceutical company based in Stamford, Connecticut, focused on developing and commercializing targeted therapies for genetically defined cancers in the United States. Founded in 2013, the company aims to bring innovative cancer treatments to the clinic by identifying actionable "driver mutations" in tumors. Its lead product candidate, larotrectinib, is an oral selective inhibitor of tropomyosin receptor kinase (TRK) and is undergoing various clinical trials for multiple cancer types, including lung, melanoma, and breast cancer. Loxo Oncology is also advancing several preclinical programs, including candidates targeting RET fusion proteins and FGFR isoforms. The company has established collaborations with several organizations to enhance its drug discovery efforts and optimize its clinical development strategies. As a subsidiary of Eli Lilly and Company, Loxo Oncology is dedicated to creating effective therapies that address specific genetic vulnerabilities in cancer patients.

LENSAR, Inc. is a commercial-stage medical device company based in Orlando, Florida, established in 2004. It specializes in the design, development, and marketing of advanced femtosecond laser systems aimed at improving cataract surgery outcomes. The company's flagship product, the LENSAR Laser with Streamline IV, enhances the precision and efficiency of refractive cataract surgery by incorporating advanced features such as superior imaging capabilities and customizable treatment planning. This system assists surgeons in managing astigmatism and optimizing refractive results through innovative technology like the proprietary Augmented Reality™ 3-D model and the IntelliAxis Refractive Capsulorhexis® feature. These advancements facilitate accurate toric intraocular lens alignment and streamline surgical workflows, ultimately improving patient outcomes. LENSAR continues to expand its platform's capabilities, enabling the treatment of additional corneal conditions and enhancing the overall surgical experience for both patients and surgeons.

LENSAR, Inc. is a commercial-stage medical device company based in Orlando, Florida, established in 2004. It specializes in the design, development, and marketing of advanced femtosecond laser systems aimed at improving cataract surgery outcomes. The company's flagship product, the LENSAR Laser with Streamline IV, enhances the precision and efficiency of refractive cataract surgery by incorporating advanced features such as superior imaging capabilities and customizable treatment planning. This system assists surgeons in managing astigmatism and optimizing refractive results through innovative technology like the proprietary Augmented Reality™ 3-D model and the IntelliAxis Refractive Capsulorhexis® feature. These advancements facilitate accurate toric intraocular lens alignment and streamline surgical workflows, ultimately improving patient outcomes. LENSAR continues to expand its platform's capabilities, enabling the treatment of additional corneal conditions and enhancing the overall surgical experience for both patients and surgeons.

Versartis is a biotechnology company based in Redwood City, California, focused on developing therapeutic proteins for endocrine disorders. The company specializes in recombinant human growth hormones and employs a novel half-life extension technology known as XTEN to enhance treatment efficacy. Versartis is advancing its lead program, VRS-317, which has recently completed enrollment in a multi-center Phase 1 clinical study targeting adult patients with growth hormone deficiency. The company aims to improve patient compliance and treatment outcomes by reducing the frequency of daily injections associated with traditional therapies. Founded in December 2008 through a joint venture with Amunix Inc. and Index Ventures, Versartis is supported by a team of drug development experts and leverages external contract services to efficiently execute its product development strategies.

TRIA Beauty, Inc. specializes in developing and selling light-based medical devices designed for consumer use in skincare and beauty treatments. The company's primary offerings include a hand-held diode laser device for permanent hair removal, a Skin Perfecting Blue Light device targeting acne-causing bacteria, a Skin Rejuvenating Laser for anti-aging, and an Age-Defying Eye Wrinkle Correcting Laser aimed at reducing fine lines around the eyes. These products leverage advanced light technology, typically used in professional dermatological treatments, allowing users to achieve salon-quality results at home. TRIA Beauty markets its products through its e-commerce platform and various indirect sales channels, including television, retail locations, and physician offices. Founded in 2003 and headquartered in Dublin, California, TRIA Beauty serves customers across multiple countries, including the United States, Japan, and several European nations. The company previously operated under the name SpectraGenics, Inc. before rebranding in 2008.

ViewRay, Inc. is a company that designs, manufactures, and markets advanced radiation therapy systems for cancer treatment. Its primary product, MRIdian, is an MRI-guided radiation therapy system that allows for simultaneous imaging and treatment of cancer patients. This innovative system integrates MRI technology, radiation delivery, and proprietary software to accurately locate and track soft-tissue tumors, enabling precise targeting while minimizing radiation exposure to surrounding healthy tissues. By providing real-time imaging during treatment, MRIdian addresses significant limitations of traditional radiation therapy methods, enhancing the safety and effectiveness of cancer treatment. ViewRay serves a diverse clientele, including university hospitals, community hospitals, private practices, government institutions, and independent cancer centers, primarily in the United States and internationally. The company was founded in 2004 and is headquartered in Oakwood, Ohio.

Esperion discovers and develops pharmaceutical products for the treatment of cardiovascular and metabolic diseases. Esperion intends to commercialize a novel class of drugs that focuses on a new treatment approach called "HDL Therapy," which is based on the Company's understanding of high-density lipoprotein, or HDL, function.

T2 Biosystems, Inc. is an in vitro diagnostics company focused on developing advanced diagnostic products for detecting pathogens and biomarkers. Utilizing its proprietary T2 Magnetic Resonance technology, the company offers rapid and accurate testing for various medical conditions directly from unpurified patient samples, including whole blood, plasma, and urine. Key products include the T2Dx Instrument for diagnosing sepsis and Lyme disease, the T2Candida Panel for identifying Candida species, and the T2Bacteria Panel for detecting bacterial pathogens linked to sepsis. Additionally, T2 Biosystems provides the T2Resistance Panel for identifying antibiotic resistance markers and is developing other diagnostic panels for multi-drug resistant pathogens and Lyme disease strains. The company collaborates with organizations like Canon U.S. Life Sciences and Allergan Sales to enhance its testing capabilities. Founded in 2006 and based in Lexington, Massachusetts, T2 Biosystems aims to improve patient care and reduce healthcare costs through its innovative diagnostic solutions.

Versartis is a biotechnology company based in Redwood City, California, focused on developing therapeutic proteins for endocrine disorders. The company specializes in recombinant human growth hormones and employs a novel half-life extension technology known as XTEN to enhance treatment efficacy. Versartis is advancing its lead program, VRS-317, which has recently completed enrollment in a multi-center Phase 1 clinical study targeting adult patients with growth hormone deficiency. The company aims to improve patient compliance and treatment outcomes by reducing the frequency of daily injections associated with traditional therapies. Founded in December 2008 through a joint venture with Amunix Inc. and Index Ventures, Versartis is supported by a team of drug development experts and leverages external contract services to efficiently execute its product development strategies.

Ambit Biosciences is a privately-held biopharmaceutical company that specializes in the discovery and development of small molecule kinase inhibitors aimed at treating cancer and inflammatory diseases. The company's lead compound, AC220, is a selective and orally bioavailable inhibitor of FMS-like tyrosine kinase-3 (FLT3), currently undergoing clinical trials for patients with relapsed or refractory acute myeloid leukemia (AML). Ambit is collaborating with Astellas Pharma Inc. to jointly develop and commercialize FLT3 kinase inhibitors across various therapeutic areas. In addition to AC220, Ambit's clinical pipeline features AC480, a pan-HER inhibitor, and AC430, an oral inhibitor of JAK2. Furthermore, the company has several preclinical candidates, including CEP-32496, a BRAF inhibitor that is licensed to Cephalon. Through its innovative approach, Ambit aims to enhance treatment outcomes for cancer patients.

Aragon Pharmaceuticals is a discovery-stage small molecule company dedicated to developing therapeutics for hormone-resistant cancers, particularly focusing on prostate and breast cancer. The company specializes in anti-endocrine therapies that target the biology of these cancers. Its research emphasizes nuclear receptor biology, medicinal chemistry, and drug discovery, with the goal of identifying and developing selective androgen receptor degraders for prostate cancer and selective estrogen receptor degraders for estrogen-sensitive breast cancer.

TRIA Beauty, Inc. specializes in developing and selling light-based medical devices designed for consumer use in skincare and beauty treatments. The company's primary offerings include a hand-held diode laser device for permanent hair removal, a Skin Perfecting Blue Light device targeting acne-causing bacteria, a Skin Rejuvenating Laser for anti-aging, and an Age-Defying Eye Wrinkle Correcting Laser aimed at reducing fine lines around the eyes. These products leverage advanced light technology, typically used in professional dermatological treatments, allowing users to achieve salon-quality results at home. TRIA Beauty markets its products through its e-commerce platform and various indirect sales channels, including television, retail locations, and physician offices. Founded in 2003 and headquartered in Dublin, California, TRIA Beauty serves customers across multiple countries, including the United States, Japan, and several European nations. The company previously operated under the name SpectraGenics, Inc. before rebranding in 2008.

Intercept Pharmaceuticals is a biopharmaceutical company dedicated to the development and commercialization of therapeutics for progressive non-viral liver diseases in the United States, Europe, and Canada. Its primary product, Ocaliva, is a farnesoid X receptor agonist approved for the treatment of primary biliary cholangitis (PBC) in adults, often used in combination with ursodeoxycholic acid. The company is also exploring Ocaliva for other conditions, including nonalcoholic steatohepatitis (NASH), and has several additional product candidates in various stages of clinical and preclinical development. Intercept has established partnerships for research and commercialization, including agreements with Sumitomo Dainippon Pharma to develop OCA for PBC and NASH in Japan and China, as well as Aralez Pharmaceuticals Canada to develop bezafibrate in the United States. The company employs various marketing strategies, utilizing an internal commercial team, contract sales organizations, and third-party distributors. Founded in 2002, Intercept Pharmaceuticals is headquartered in New York, New York.

Agile Therapeutics is a women's healthcare company dedicated to addressing the unmet health needs of women through the development and commercialization of prescription contraceptive products. The company's lead product, Twirla, is a once-weekly transdermal patch that delivers a combination of levonorgestrel and ethinylestradiol, providing a non-daily contraceptive option. In addition to Twirla, Agile Therapeutics is advancing a pipeline of related products, including various regimens designed to offer customizable menstrual cycle management options, such as AG200-ER for extended cycles and AG200-SP for lighter periods. The firm's proprietary Skinfusion technology facilitates effective drug delivery through the skin. Headquartered in Princeton, New Jersey, Agile Therapeutics aims to enhance women's reproductive health by providing innovative contraceptive solutions.

PreCision Dermatology is a rapidly growing company dedicated to advancing skincare through innovative therapies. It focuses on developing products that enhance the delivery of active ingredients to the skin, reducing side effects and strengthening the skin's natural barrier. The company's portfolio addresses various dermatological conditions like atopic dermatitis, acne, and rosacea. PreCision Dermatology expands its offerings through internal research, acquisitions, licensing agreements, and strategic partnerships.

Kuros Biosciences AG is a biopharmaceutical company based in Schlieren, Switzerland, dedicated to the discovery, development, and commercialization of innovative products for tissue repair and regeneration. Founded in 2000 as a spin-off from the Eidgenössische Technische Hochschule Zürich, Kuros has developed a robust pipeline of biopharmaceuticals targeting chronic diseases. Its key products include Neuroseal, a novel biomaterial for dural sealing, and the MagnetOs family of bone graft substitutes used in orthopedic, spinal, and dental applications. MagnetOs is approved for use in the EU and the US, with further formulations under development for regulatory submission. Kuros also has a range of clinical-stage products, including KUR-111 and KUR-113, which have completed Phase II clinical trials for treating specific bone fractures. The company has engaged in significant clinical research, enrolling over 600 patients in multinational trials, generating promising data regarding safety and efficacy in various applications, particularly within orthobiologics.

ViewRay, Inc. is a company that designs, manufactures, and markets advanced radiation therapy systems for cancer treatment. Its primary product, MRIdian, is an MRI-guided radiation therapy system that allows for simultaneous imaging and treatment of cancer patients. This innovative system integrates MRI technology, radiation delivery, and proprietary software to accurately locate and track soft-tissue tumors, enabling precise targeting while minimizing radiation exposure to surrounding healthy tissues. By providing real-time imaging during treatment, MRIdian addresses significant limitations of traditional radiation therapy methods, enhancing the safety and effectiveness of cancer treatment. ViewRay serves a diverse clientele, including university hospitals, community hospitals, private practices, government institutions, and independent cancer centers, primarily in the United States and internationally. The company was founded in 2004 and is headquartered in Oakwood, Ohio.

LENSAR, Inc. is a commercial-stage medical device company based in Orlando, Florida, established in 2004. It specializes in the design, development, and marketing of advanced femtosecond laser systems aimed at improving cataract surgery outcomes. The company's flagship product, the LENSAR Laser with Streamline IV, enhances the precision and efficiency of refractive cataract surgery by incorporating advanced features such as superior imaging capabilities and customizable treatment planning. This system assists surgeons in managing astigmatism and optimizing refractive results through innovative technology like the proprietary Augmented Reality™ 3-D model and the IntelliAxis Refractive Capsulorhexis® feature. These advancements facilitate accurate toric intraocular lens alignment and streamline surgical workflows, ultimately improving patient outcomes. LENSAR continues to expand its platform's capabilities, enabling the treatment of additional corneal conditions and enhancing the overall surgical experience for both patients and surgeons.

ADMA Biologics, Inc. is a biopharmaceutical company focused on developing, manufacturing, and marketing specialty plasma-derived biologics aimed at treating immune deficiencies and infectious diseases in the United States. The company offers a range of products, including BIVIGAM and ASCENIV, both intravenous immune globulin therapies for primary humoral immunodeficiency, as well as Nabi-HB, which is used for acute exposure to Hepatitis B. ADMA is also involved in the development of additional plasma-derived therapeutics, particularly targeting infections like S. pneumonia. To support its operations, the company runs FDA-licensed source plasma collection facilities known as ADMA BioCenters, which contribute to the supply of plasma necessary for its product manufacturing. ADMA Biologics distributes its products through independent distributors, sales agents, specialty pharmacies, and other healthcare providers. Founded in 2004 and based in Ramsey, New Jersey, ADMA is dedicated to serving niche patient populations, particularly those with compromised immune systems.

CeNeRx BioPharma, Inc., a drug development company, engages in identifying, developing, and commercializing therapeutics to treat diseases related to neurotransmitters and the nervous system. The company's product pipeline includes Tyrima, CX2614, and CX009, which are reversible inhibitors of monoamine oxidase- A that are used for the treatment of mood, anxiety, and somatic disorders. It focuses on developing therapeutics to treat diseases related to neurotransmitters, including anxiety, bipolar disorder, dementia, depression, epilepsy, neuropathic pain, schizophrenia, and Parkinson's and Alzheimer's diseases. The company was founded in 2005 and is based in Cary, North Carolina.

Roka Bioscience specializes in the development of rapid and accurate molecular assays and instrument systems aimed at the food safety industry. The company's latest innovation, the Atlas System, introduces advanced molecular rapid pathogen testing, which enhances laboratory efficiency through automation and user-friendly design. By focusing on innovative testing solutions, Roka Bioscience aims to assist food manufacturers in minimizing risks, safeguarding their brands, and addressing the growing demands for testing in the sector.

ViewRay, Inc. is a company that designs, manufactures, and markets advanced radiation therapy systems for cancer treatment. Its primary product, MRIdian, is an MRI-guided radiation therapy system that allows for simultaneous imaging and treatment of cancer patients. This innovative system integrates MRI technology, radiation delivery, and proprietary software to accurately locate and track soft-tissue tumors, enabling precise targeting while minimizing radiation exposure to surrounding healthy tissues. By providing real-time imaging during treatment, MRIdian addresses significant limitations of traditional radiation therapy methods, enhancing the safety and effectiveness of cancer treatment. ViewRay serves a diverse clientele, including university hospitals, community hospitals, private practices, government institutions, and independent cancer centers, primarily in the United States and internationally. The company was founded in 2004 and is headquartered in Oakwood, Ohio.

T2 Biosystems, Inc. is an in vitro diagnostics company focused on developing advanced diagnostic products for detecting pathogens and biomarkers. Utilizing its proprietary T2 Magnetic Resonance technology, the company offers rapid and accurate testing for various medical conditions directly from unpurified patient samples, including whole blood, plasma, and urine. Key products include the T2Dx Instrument for diagnosing sepsis and Lyme disease, the T2Candida Panel for identifying Candida species, and the T2Bacteria Panel for detecting bacterial pathogens linked to sepsis. Additionally, T2 Biosystems provides the T2Resistance Panel for identifying antibiotic resistance markers and is developing other diagnostic panels for multi-drug resistant pathogens and Lyme disease strains. The company collaborates with organizations like Canon U.S. Life Sciences and Allergan Sales to enhance its testing capabilities. Founded in 2006 and based in Lexington, Massachusetts, T2 Biosystems aims to improve patient care and reduce healthcare costs through its innovative diagnostic solutions.

Pharmaron Beijing Co Ltd is a research and development service provider in the life sciences sector, specializing in a comprehensive range of services for drug discovery, preclinical, and clinical development. The company supports various therapeutic modalities, including small molecules, biologics, and cell and gene therapies. Pharmaron's offerings encompass laboratory chemistry, biosciences, drug metabolism and pharmacokinetics (DMPK), pharmacology, drug safety assessments, and clinical development services. Its operations are divided into several segments, with laboratory services generating the highest revenue. By providing these essential services, Pharmaron plays a crucial role in advancing the drug development process for its clients.

TRIA Beauty, Inc. specializes in developing and selling light-based medical devices designed for consumer use in skincare and beauty treatments. The company's primary offerings include a hand-held diode laser device for permanent hair removal, a Skin Perfecting Blue Light device targeting acne-causing bacteria, a Skin Rejuvenating Laser for anti-aging, and an Age-Defying Eye Wrinkle Correcting Laser aimed at reducing fine lines around the eyes. These products leverage advanced light technology, typically used in professional dermatological treatments, allowing users to achieve salon-quality results at home. TRIA Beauty markets its products through its e-commerce platform and various indirect sales channels, including television, retail locations, and physician offices. Founded in 2003 and headquartered in Dublin, California, TRIA Beauty serves customers across multiple countries, including the United States, Japan, and several European nations. The company previously operated under the name SpectraGenics, Inc. before rebranding in 2008.

NextWave Pharmaceuticals is a Cupertino, California-based pharmaceutical company that specializes in the development and commercialization of innovative drug delivery technologies. The company primarily focuses on creating once-daily liquid medications for the treatment of attention deficit/hyperactivity disorder (ADHD). By leveraging its proprietary technology, NextWave aims to provide effective treatment options that enhance patient compliance and address disorders related to the central nervous system.

ViewRay, Inc. is a company that designs, manufactures, and markets advanced radiation therapy systems for cancer treatment. Its primary product, MRIdian, is an MRI-guided radiation therapy system that allows for simultaneous imaging and treatment of cancer patients. This innovative system integrates MRI technology, radiation delivery, and proprietary software to accurately locate and track soft-tissue tumors, enabling precise targeting while minimizing radiation exposure to surrounding healthy tissues. By providing real-time imaging during treatment, MRIdian addresses significant limitations of traditional radiation therapy methods, enhancing the safety and effectiveness of cancer treatment. ViewRay serves a diverse clientele, including university hospitals, community hospitals, private practices, government institutions, and independent cancer centers, primarily in the United States and internationally. The company was founded in 2004 and is headquartered in Oakwood, Ohio.

Zeltiq Aesthetics, founded in 2005 and headquartered in Pleasanton, California, is a medical technology company focused on developing non-invasive solutions for the reduction of unwanted fat tissue. The company's flagship product, the CoolSculpting system, employs a patented technology known as Cryolipolysis, which utilizes controlled cooling to selectively target and eliminate fat cells while preserving surrounding skin and tissue. This FDA-cleared treatment provides a non-surgical option for individuals seeking to reduce stubborn fat bulges. Zeltiq distributes its products through a direct sales force and a network of distributors, catering primarily to dermatologists, plastic surgeons, and aesthetic specialists across North America, Europe, the Asia-Pacific, and Latin America. The company was previously known as Juniper Medical, Inc. before rebranding in 2007. As of 2017, Zeltiq operates as a subsidiary of Allergan plc.

Aragon Pharmaceuticals is a discovery-stage small molecule company dedicated to developing therapeutics for hormone-resistant cancers, particularly focusing on prostate and breast cancer. The company specializes in anti-endocrine therapies that target the biology of these cancers. Its research emphasizes nuclear receptor biology, medicinal chemistry, and drug discovery, with the goal of identifying and developing selective androgen receptor degraders for prostate cancer and selective estrogen receptor degraders for estrogen-sensitive breast cancer.

Xanodyne Pharmaceuticals, Inc. operates as an integrated specialty pharmaceutical company that offers developing and commercializing products in women’s healthcare and pain management in the United States.The company was formerly known as Xanodyne Pharmacal, Inc. and changed the name to Xanodyne Pharmaceuticals, Inc. in February, 2004. Xanodyne Pharmaceuticals, Inc. was incorporated in 2000 and is based in Newport, Kentucky.

Asensus Surgical is a medical device company focused on enhancing minimally invasive surgery through digital laparoscopy. By digitizing the interface between surgeons and patients, the company incorporates advanced technologies such as augmented intelligence, connectivity, and robotics into surgical procedures. Their flagship product, the Senhance Surgical System, is notable for being the first machine vision system designed for robotic surgery. This system is supported by the Intelligent Surgical Unit, which facilitates augmented intelligence in surgery. Asensus Surgical aims to address various clinical, cognitive, and economic challenges faced in surgical practices, ultimately improving patient outcomes through innovative solutions in digital laparoscopy.

Cempra seeks to discover and develop well-differentiated medicines that cure bacterial infections and improve the quality of life for those with chronic illnesses. The company balances near-term product development opportunities, including the macrolide CEM-101, while investing in future products from new technologies to derive the next generation of antibiotics.

Bridge Pharmaceuticals is a drug development research organization based in Gaithersburg, Maryland. It provides toxicology and pharmacology services to support investigational new drug applications on a global scale.

TRIA Beauty, Inc. specializes in developing and selling light-based medical devices designed for consumer use in skincare and beauty treatments. The company's primary offerings include a hand-held diode laser device for permanent hair removal, a Skin Perfecting Blue Light device targeting acne-causing bacteria, a Skin Rejuvenating Laser for anti-aging, and an Age-Defying Eye Wrinkle Correcting Laser aimed at reducing fine lines around the eyes. These products leverage advanced light technology, typically used in professional dermatological treatments, allowing users to achieve salon-quality results at home. TRIA Beauty markets its products through its e-commerce platform and various indirect sales channels, including television, retail locations, and physician offices. Founded in 2003 and headquartered in Dublin, California, TRIA Beauty serves customers across multiple countries, including the United States, Japan, and several European nations. The company previously operated under the name SpectraGenics, Inc. before rebranding in 2008.

Esperion discovers and develops pharmaceutical products for the treatment of cardiovascular and metabolic diseases. Esperion intends to commercialize a novel class of drugs that focuses on a new treatment approach called "HDL Therapy," which is based on the Company's understanding of high-density lipoprotein, or HDL, function.

ViewRay, Inc. is a company that designs, manufactures, and markets advanced radiation therapy systems for cancer treatment. Its primary product, MRIdian, is an MRI-guided radiation therapy system that allows for simultaneous imaging and treatment of cancer patients. This innovative system integrates MRI technology, radiation delivery, and proprietary software to accurately locate and track soft-tissue tumors, enabling precise targeting while minimizing radiation exposure to surrounding healthy tissues. By providing real-time imaging during treatment, MRIdian addresses significant limitations of traditional radiation therapy methods, enhancing the safety and effectiveness of cancer treatment. ViewRay serves a diverse clientele, including university hospitals, community hospitals, private practices, government institutions, and independent cancer centers, primarily in the United States and internationally. The company was founded in 2004 and is headquartered in Oakwood, Ohio.

Topaz Pharmaceuticals, now a part of Sanofi, is a pharmaceutical company that focuses on developing and manufacturing products aimed at addressing children's health issues. Founded in 2005 and headquartered in Horsham, Pennsylvania, the company offers a variety of medications for conditions such as head lice, acne, and infections. Additionally, Topaz Pharmaceuticals produces vaccines to protect against common childhood diseases, thereby providing essential health solutions for doctors and parents concerned about the well-being of children.

Paratek Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company based in Boston, Massachusetts, specializing in the development and commercialization of innovative therapies derived from novel tetracycline chemistry. The company’s lead product, NUZYRA, is a broad-spectrum antibiotic administered in both oral and intravenous forms, targeting adult patients with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections. Another significant product, SEYSARA, is designed for the treatment of moderate to severe acne vulgaris. Paratek has received Qualified Infectious Disease Product designation from the U.S. Food and Drug Administration for its lead antibiotic, reflecting its commitment to addressing urgent public health threats, including antibiotic resistance. The company maintains various collaboration agreements, including partnerships with Zai Lab and Allergan, as well as research agreements with academic institutions and military organizations, to further its mission in combating infectious diseases and exploring additional therapeutic areas such as multiple sclerosis and systemic inflammatory diseases.

Xanodyne Pharmaceuticals, Inc. operates as an integrated specialty pharmaceutical company that offers developing and commercializing products in women’s healthcare and pain management in the United States.The company was formerly known as Xanodyne Pharmacal, Inc. and changed the name to Xanodyne Pharmaceuticals, Inc. in February, 2004. Xanodyne Pharmaceuticals, Inc. was incorporated in 2000 and is based in Newport, Kentucky.

Cempra seeks to discover and develop well-differentiated medicines that cure bacterial infections and improve the quality of life for those with chronic illnesses. The company balances near-term product development opportunities, including the macrolide CEM-101, while investing in future products from new technologies to derive the next generation of antibiotics.

BioRelix, Inc., a biopharmaceutical company, engages in the discovery and development of anti-biotic drug candidates for the treatment of infectious diseases in the United States. It develops a portfolio of riboswitch-based therapeutic agents to overcome the lethal and devastating causes of bacterial infections. The company was founded in 2005 and is based in New Haven, Connecticut.

Bioenvision a biopharmaceutical company, engages in the acquisition, development, and marketing of compounds and technologies primarily for the treatment of cancer. Its lead products include Evoltra (clofarabine) which has marketing approval in both the European Union and United States for the treatment of pediatric relapsed or refractory acute lymphoblastic leukemia and Modrenal (trilostane), which has marketing approval in the United Kingdom for the treatment of post-menopausal breast cancer following relapse to initial hormone therapy.

The Natural Dentist, Inc., founded in 1995 and based in Medford, Massachusetts, specializes in manufacturing oral care products, including mouth rinses and toothpastes. The company, which was previously known as Woodstock Natural Products Inc. before rebranding in 2005, provides its products through various retail channels, including physical stores and online platforms. In 2010, The Natural Dentist was acquired by Revive Personal Products Company. The company is part of a broader portfolio that includes over-the-counter consumer healthcare brands, reflecting its commitment to promoting oral health and hygiene.

Sirion Therapeutics is a biopharmaceutical company, engaged in developing, and commercializing of products for the protection of eyesight.